Passage Bio, Inc. (PASG) 股票分析

公司概述

Passage Bio, Inc. operates as a genetic medicines company focused on the development of gene therapies specifically designed for central nervous system diseases, utilizing functional gene encoding approaches to treat deficiencies such as those in progranulin. The company functions within the broader Healthcare sector, specifically in the Biotechnology industry, a landscape characterized by high research and development costs and significant regulatory hurdles before products reach commercialization. Its current scale is defined by a market capitalization of $29.80 million and an employee base of 24 individuals, while reported annual revenue figures are not disclosed in the available financial data. These valuation metrics indicate that the company is a small-cap entity with limited historical sales data, suggesting it is likely in a pre-revenue or early-stage development phase where market value is driven primarily by intellectual property potential rather than current cash flow generation.

财务健康

The company reports a net income of $-45,522,000 and an EBITDA of $-42,423,000 over the trailing twelve months, with revenue figures unavailable for specific calculation. The substantial gap between the reported negative net income and the relatively smaller negative EBITDA reveals a cost structure heavily impacted by non-operating expenses or significant interest costs, as EBITDA strips out interest and taxes to focus on operational profitability. Free cash flow stands at $-18,799,376, indicating that the company is consuming cash reserves to fund its operations and research activities, which severely limits its immediate financial flexibility and necessitates access to capital markets or existing liquidity. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, a figure that typically signifies that the company has not yet achieved commercial sales or that revenue is negligible relative to costs, rendering traditional margin analysis inapplicable. In terms of balance sheet leverage, the company holds $46.30 million in cash against $24.01 million in debt, resulting in a debt-to-equity ratio of 128.02, which suggests a highly leveraged position relative to equity, though the high cash balance provides a buffer against this debt load. The current ratio is 2.07, indicating that the company possesses more than double the liquid assets required to cover its short-term obligations, thereby demonstrating adequate short-term liquidity despite the heavy debt burden. Return on Equity is -113.8% and Return on Assets is -32.8%, metrics that reveal management is currently destroying value per share and utilizing assets to generate negative returns, a common characteristic of biotechnology firms in deep development stages that have not yet crossed the revenue threshold.

估值评估

Valuation multiples for Passage Bio, Inc. are distorted by its lack of profitability, as the P/E Ratio (TTM) is N/A due to negative earnings, while the Forward P/E is listed at -1.06, implying that future earnings projections are expected to remain negative or that the market is pricing in a significant turnaround required before positive earnings can be realized. The price-to-book ratio stands at 1.58, indicating that the market values the company at a 58% premium over its net asset book value, which may reflect the high value placed on its intangible intellectual property and pipeline potential rather than tangible assets. Alternative valuation metrics such as the Price-to-Sales ratio, which is N/A, and the EV/EBITDA of -0.18, further complicate standard valuation comparisons, suggesting that traditional relative valuation methods are ineffective for assessing this company's current worth without significant adjustments for revenue generation. The stock's 52-week price range fluctuates between a high of $20.00 and a low of $5.12, providing a context for current market sentiment and volatility within the biotech sector. The beta value of 1.76 indicates that the stock exhibits significantly higher volatility than the broader market, moving with a magnitude 76% greater than the market average, which exposes investors to substantial price swings during periods of market turbulence.

Growth & Income

Passage Bio, Inc. reports N/A for both Revenue Growth (YoY) and Earnings Growth (YoY), reflecting the absence of comparable prior period data or established revenue streams typical of early-stage biotechnology firms. Because the company does not pay dividends, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, it follows a strategy of reinvesting all available capital and earnings back into research and development to advance its gene therapy pipeline rather than distributing income to shareholders. The lack of dividend income combined with negative earnings growth underscores that the company's primary growth profile is tied entirely to the potential commercial success of its drug candidates, PBFT02 and PBGM01, rather than current financial performance. The overall growth and income profile is characterized by high risk and high potential reward, where investor returns are contingent on the successful execution of clinical trials and future product approvals rather than current cash flow generation or dividend payouts.